R&D Towards better quality of life, GNT Pharma
Pipeline
Global New Drug Development
Pipeline
FLUSALAZINE Flusalazine / Drug for inflammatory - respiratory diseases and pain
Overview
-
Drag from side to side.
- A novel anti-inflammatory drug documented to be safe in cultured cells and animals and discovered using a ligand- and structure-based drug design to reduce the gastrointestinal side effects of aspirin and the granulocytopenia side effect of sulfasalazine.
- Pharmacological action: Anti-inflammatory + tissue-protective actions as a pro-drug of crisdesalazine, optimized for the treatment of systemic inflammatory and respiratory diseases.
- Efficacy has been verified in animal models of acute, inflammatory, and neuropathic pain.
- Efficacy has been verified in animal models of painful inflammatory diseases such as gastritis, enteritis, and pancreatitis.
- Efficacy has been verified in animal models of chronic obstructive pulmonary disease (COPD) and asthma (patent application in December 2021).
Indications
- Chronic Inflammatory Disease
- Pancreatitis
- Enteritis
- Gastritis
- Gloves and Socks Syndrome
- Asthma
Comparison of Flusalazine and current drugs for inflammation & pain
-
Drag from side to side.
| GNT Pharma | Pfizer | Merk | ||
|---|---|---|---|---|
| Drug | Flusalazine | Celebrex | Vioxx | |
| Pharmacological mechanism and efficacy | Anti-inflammation, Analgesic action | mPGES-1 inhibition | COX-2 inhibition | COX-2 inhibition |
| Tissue protection | ROS toxicity inhibition | - | - | |
| Indications | Arthritis | Arthritis | Arthritis | |
| Pancreatitis | - | - | ||
| COPD, Asthma | - | - | ||
| Development/sales status | IND Preparation | $2.3 billion (2003) $3.3 billion (2004) $2.7 billion (2012) |
$2.5 billion (2003) | |
| Adverse effect | No cardiovascular adverse effects No gastrointestinal adverse effects |
Cardiovascular adverse effects (2005) Gastrointestinal adverse effects (2012) |
Market withdrawal due to cardiovascular adverse effects (2004) | |
| Remark | Safety verification in phase 1 clinical trial of active substances | Non-clinical stage of mPGES-1 inhibitor | Discovery step of mPGES-1 inhibitor | |